ArticleMolecular nutrition & food research2013
Type B CpG oligodeoxynucleotides induce Th1 responses to peanut antigens: modulation of sensitization and utility in a truncated immunotherapy regimen in mice.
Article in Molecular nutrition & food research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 44 citations in OpenAlex.
- The role of biologics in pediatric food allergy and eosinophilic gastrointestinal disorders.The Journal of allergy and clinical immunology · 2023Review
- B cells and food allergy.Current opinion in pediatrics · 2021Review
- Als3-Th-cell-epitopes plus the novel combined adjuvants of CpG, MDP, and FIA synergistically enhanced the immune response of recombinant TRAP derived from Staphylococcus aureus in mice.Immunity, inflammation and disease · 2021Article
- Protein Immunization Induces Memory CD4Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Mouse Models of Food Allergy in the Pursuit of Novel Treatment Modalities.Frontiers in allergy · 2021Review
- IL-2-Agonist-Induced IFN-γ Exacerbates Systemic Anaphylaxis in Food Allergen-Sensitized Mice.Frontiers in immunology · 2020Article
- Nasal peanut+ CpG immunotherapy enhances peanut-specific IFN-γ in Th2 cells and IL-10 in non-Th2 cells in mice.Allergy · 2019Article
- Microbial Adjuncts for Food Allergen Immunotherapy.Current allergy and asthma reports · 2019Review
- Glycosylated nanostructures in sublingual immunotherapy induce long-lasting tolerance in LTP allergy mouse model.Scientific reports · 2019Article
- Genetic diversity between mouse strains allows identification of the CC027/GeniUnc strain as an orally reactive model of peanut allergy.The Journal of allergy and clinical immunology · 2019Article
- Enhancing the Safety and Efficacy of Food Allergy Immunotherapy: a Review of Adjunctive Therapies.Clinical reviews in allergy & immunology · 2018Review
- Hematopoietic reconstitution of neonatal immunocompetent mice to study conditions with a perinatal window of susceptibility.Scientific reports · 2018Article
- Adjuvanted Immunotherapy Approaches for Peanut Allergy.Frontiers in immunology · 2018Review
- The rise of food allergy: Environmental factors and emerging treatments.EBioMedicine · 2016Review
- Future Therapies for IgE-Mediated Food Allergy.Current pediatrics reports · 2014Article
- Emerging therapies for food allergy.The Journal of clinical investigation · 2014Review
- Developing therapies for peanut allergy.International archives of allergy and immunology · 2014Review
- B-cell epitopes in GroEL of Francisella tularensis.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
scopePeanut allergy stems from a Th2-biased immune response to peanut allergens leading to IgE production and allergic reactions upon ingestion. METHODS AND
resultsA model of peanut allergy in C3H/HeJ mice was used to assess whether type A, B, or C CpG oligodeoxynucleotide (ODN) molecules would be effective in: (i) a prophylactic approach to prevent peanut allergy when administered simultaneously with a Th2-skewing adjuvant, and (ii) a therapeutic model to allow for shortened immunotherapy. Type B ODNs were extremely effective in inhibiting anaphylaxis in the sensitization protocol as evidenced by differences in symptom scores, body temperature, and mouse mast cell protease 1 release compared to sham treatment. In the therapeutic model, co-administration of type B ODN plus peanut proteins was highly effective in reducing anaphylactic reactions in mice with established peanut allergy. The therapeutic effect was accompanied by an increase in IFN-γ and peanut-IgG2a, without a significant decrease in peanut IgE or IL-4 responses.
conclusionCpG ODNs, especially type B, were highly effective in inducing Th1 responses in mice undergoing induction of peanut allergy, as well as in mice undergoing therapy for established peanut allergy. Interestingly, the IgE response was not significantly altered, suggesting that IgG antibodies may be enough to prevent peanut-induced anaphylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.